Nantilus
Evaluating Clinical Research : All that Glitters is not Gold
The objective of this book is to make its readers better informed and more critical consumers of clinical research to help them recognize the strengths and the weaknesses of scientific publications. In doing so, the reader will be able to distinguish patient-important and methodologically sound stud...
| Auteurs principaux : | , |
|---|---|
| Format : | Livre |
| Langue : | anglais |
| Titre complet : | Evaluating Clinical Research : All that Glitters is not Gold / Bengt D. Furberg and Curt D. Furberg |
| Publié : |
New York, NY :
Springer New York
, 2007 Cham : Springer Nature |
| Accès en ligne : |
Accès Nantes Université
Accès direct soit depuis les campus via le réseau ou le wifi eduroam soit à distance avec un compte @etu.univ-nantes.fr ou @univ-nantes.fr |
| Note sur l'URL : | Accès sur la plateforme de l'éditeur Accès sur la plateforme Istex |
| Condition d'utilisation et de reproduction : | Conditions particulières de réutilisation pour les bénéficiaires des licences nationales : chttps://www.licencesnationales.fr/springer-nature-ebooks-contrat-licence-ln-2017 |
| Sujets : | |
| Documents associés : | Autre format:
Evaluating Clinical Research Autre format: New methods and results in non-linear field equations |
- What is the purpose of this book?
- Why is benefit-to-harm balance essential to treatment decisions?
- What are the strengths of randomized controlled clinical trials?
- What are the weaknesses of randomized controlled clinical trials?
- Do meta-analyses provide the ultimate truth?
- What are the strengths of observational studies?
- What are the weaknesses of observational studies?
- Were the scientific questions stated in advance?
- Were the treatment groups comparable initially?
- Why is blinding/masking so important?
- How is symptomatic improvement measured?
- Is it really possible to assess quality of life?
- What is the value of biologic markers in drug evaluation?
- How are adverse drug reactions measured?
- How representative are study subjects in clinical trials?
- What happened to the study subjects who disappeared from the analysis?
- How reliable are active-control trials?
- How informative are composite outcomes?
- Do changes in biologic markers predict clinical benefit?
- How trustworthy are the authors?
- Does publication in a reputable scientific journal guarantee quality?
- Is it necessary to be a biostatistician to interpret scientific data?
- Are all drugs of a class interchangeable?
- How much confidence can be placed on economic analysis?
- How should I handle the massive flow of information?
- How well is research translated into clinical care?.